Therapeutic Peptides Alternative Drug Delivery Platforms

In the second part of a two-piece article Rodney Lax (Senior Director of Business Development, PolyPeptide Group) and Christopher Meenan (CEO, Araya Biosciences) consider how alternative drug delivery platforms for administering peptides can add value to a peptide product. Many new delivery platform technologies are being developed. These include intra/transdermal, nasal, oral, pulmonary, and topical administration as well as implantable devices. The authors discuss these and present some specific examples. It is evident that alternative delivery technologies do provide ‘added value’ in regards to being more favourable to the patient and increasing a drug’s product life cycle. However, ultimately the health insurance companies who determine whether the ‘added value’ is affordable.

To read the full article, please click on the link below:
Therapeutic Peptides Alternative Drug Delivery Platforms